Pregnancy ,Medical abortion, Nitroglycerin ., Misoprostol ,cervical ripening. XV Pregnancy, childbirth and the puerperium ,Medical abortion
Conditions
Interventions
Intervention 1: Intervention groups: Group A 85 people will receive 400 mg single dose of trinitroglycerin tablets of Dana Pharmaceutical Company vaginally. Intervention 2: Intervention group: Group B
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: After obtaining full consent to participate in the study, pregnant women are candidates for curettage with a gestational age of less than 14 weeks who have a reason for termination of pregnancy (missed abortion, medical abortion) based on the case file documents And have normal vital signs including no fever( less than 38 ° C), normal heart rate between 70 and 100 and systolic blood pressure between 100 and 130. Also have a history of uterine scarring at most once, no drug abuse, no bleeding (based on initial examination )Lack of coagulation disorder or recent history of anticoagulants, no active liver disease, cardiovascular disease, uncontrolled seizures, history of glaucoma, adrenal insufficiency are the conditions for inclusion in the study.
Exclusion criteria
Exclusion criteria: Patients who wish to have a medical abortion and are not candidates for curettage surgery for any reason. Women who have more than one history of uterine scarring are not included in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervical ripening. Timepoint: Initial examination and 4 hours after receiving the drug. Method of measurement: Hegar Bogey No. 8 passes through the cervix. | — |
Secondary
| Measure | Time frame |
|---|---|
| Requires mechanical dilatation. Timepoint: During curettage. Method of measurement: HegarBogey No. 8 passes through the cervix.;Possible side effects (diarrhea, chills, abdominal pain, headache, hypotension and palpitations). Timepoint: Every 4 hours during hospitalization. Method of measurement: Questioning the patient, examination, control of vital signs. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhazaleh Ghorbani
Rasht University of Medical Sciences
Outcome results
None listed